Michael B. Hoffman holds the role of Chairman and CEO at Translational Development Acquisition Corp. (TDAC). Hoffman's filing history also covers Annovis Bio, Inc. (ANVS). Hoffman has reported 11 insider filings with the SEC since 2025. The most recent filing was in May 2026.
Every role Michael B. Hoffman has reported on a Form 4, reconstructed from the filings themselves. Reporting insiders must state their relationship to the issuer (officer title, director seat, or 10% ownership) on every filing.
Translational Development Acquisition Corp. (TDAC)1 filingAnnovis Bio, Inc. (ANVS)10 filingsLatest filing:
Michael B. Hoffman is Chairman and CEO, Director of Translational Development Acquisition Corp. (TDAC). 11 SEC Form 4 filings on record going back to 2025, most recently on 29 May 2026. Most recent open-market trade: bought $104K of ANVS on 22 May 2026. Lifetime open-market purchases: $3.95M. Historical track record: 3/5 stars across 13 tracked purchases.
Every recent SEC Form 4 transaction Michael B. Hoffman has reported, most recent first.
InsiderAlpha computes a forward-return-based score for every insider with enough Form 4 purchase history. The metrics below reflect realized performance after each tracked open-market purchase.
| Metric | Value |
|---|---|
| InsiderAlpha rating | ★★★☆☆ (3/5) |
| Total purchases tracked | 13 |
| Purchases with forward-return data | 13 |
| 30-day win rate | 31% |
| 90-day win rate | 23% |
| Avg 5-day return | +11.08% |
| Avg 30-day return | +9.97% |
| Avg 90-day return | -18.80% |
| Best 30-day return |
InsiderAlpha's records for Michael B. Hoffman go back to 2025: 11 primary Form 4 filings, an average of 5.5 per year. The typical open-market purchase is $303K (13 buys totaling $3.95M). The largest single buy on record is $2.00M of ANVS in 2025. No recorded transaction carries a Rule 10b5-1 plan flag. An absent flag does not establish whether a transaction was pre-arranged or discretionary.
Insiders who reported open-market trades in the last 12 months at the companies Michael B. Hoffman files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Michael B. Hoffman is a corporate insider, tracked as Chairman and CEO, Director of Translational Development Acquisition Corp. (TDAC). InsiderAlpha holds 11 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
The most recent primary Form 4 on record is dated 29 May 2026, one of 11 filings going back to 2025.
Recorded transactions: 13 open-market purchases ($3.95M) and 0 open-market sales across all tracked filings.
Across 13 tracked purchases, Michael B. Hoffman averaged +10.0% avg 30-day return with a 31% 30-day win rate. InsiderAlpha rates the track record at 3/5 stars.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial
$ANVS Annovis Bio, Inc.2.6K shares @ $1.75$4K
| +142.86% |